Pharmaceutical Stocks

Pharmaceutical stocks have grown tremendously as medicine advances. With diseases like Covid-19, diabetes, liver disease and other illnesses affecting more and more of the population, pharmaceutical companies are racing to find cures – further advancing medicine and driving pharma stock prices higher.

Big Pharma corporations like AstraZeneca, Merck & Co., Pfizer, and Johnson & Johnson are leading the charge against the novel coronavirus, competing with smaller biotech names — such as Moderna and Novavax. The race to find a Covid-19 vaccine has sent both pharma and biotech stocks to the moon.

Healthcare Stocks: No Longer a Sure Thing

By Daniel Putnam, InvestorPlace Contributor
Healthcare stocks have outperformed in recent years, but investors need to be selective with valuations that now are at richer levels.

MRK: Merck Stock a Strong Performer In the Pharma Space

By Louis Navellier, Editor, Growth Investor
Merck is one the most high profile companies in the pharmaceutical industry, and Merck stock is well worth a look for investors. I rate it a buy today.

BDSI Stock – New Chronic Pain Drug Sends BioDelivery Soaring

By Christopher Freeburn, InvestorPlace Writer
Good results from a late-stage trial for a drug from BioDelivery Sciences sent BDSI stock surging in Friday trading.

Under Obamacare, Risks Grow for High-Margin Drug Stocks

By Hilary Kramer, Editor, GameChangers
The implementation of Obamacare means that reimbursement rates for certain drugs will be cut. Here's what that means for drug stocks like Questcor.

ICPT: Time to Catch a Rising Star With Intercept Stock?

By Hilary Kramer, Editor, GameChangers
It's never too late to invest in a long-term winner, and pharmaceutical player Intercept is on a long-term run. Here's why you should join the race...

ACT: Actavis’s Growth Potential Anything But Generic

By Louis Navellier, Editor, Growth Investor
Pharmaceutical company Actavis is at the forefront on the production of biologic drugs, and stands to profit from them well into the future. It's a buy!

The One Stock You Must Sell Now Is Eli Lilly

By Traders Reserve
Eli Lilly's in a position where patents are coming off faster than new products are coming on board, a bad sign for a stock you should sell right now....

5 Pharma Stocks to Buy for Big Dividends

By James Brumley, InvestorPlace Feature Writer
Drugmakers aren't known for big dividends, but the pharmaceutical industry can actually offer something for income investors.

Alzheimer’s Stocks Are a Stealth Opportunity

By James Brumley, InvestorPlace Feature Writer
Alzheimer's stocks could mean huge rewards for investors, but as always, you have to pick the right ones. Here are three with solid prospects.

Don’t Buy Orexigen on Diet Pill Hopes

By James Brumley, InvestorPlace Feature Writer
Orexigen Therapeutics joins VIVUS and Arena Pharmaceuticals in an industry that's brought nothing but disappointment to investors: weight-loss drugs.

Why Shares of SRPT Stock Sank 65%

By Christopher Freeburn, InvestorPlace Writer
Sarepta Therapeutics stock plunged in Tuesday trading on a widening quarterly loss and a negative report on a key drug from the FDA.

Regeneron Stock Is Winning on Two Fronts

By Serge Berger, InvestorPlace Contributor
Regeneron stock has continually rewarded the medium- and longer-term bulls, and following REGN earnings Tuesday, the good times are primed to keep rolling.

Generate Income on a Plummeting Pharma Stock

By Michael Shulman, Editor, Options Income Blueprint
QCOR is down a whopping 15% on the news that the Fed is investigating them again. Use the news to generate income with puts.

5 Pet Stocks Fetching Big Returns

By Carla Lake, InvestorPlace Staff
Pet stocks have been on a wild run this year, with some biotechs at least doubling in value. Here are the five hottest players in the space so far in 2013.

Q3 Earnings Roundup for Pharmaceutical Stocks

By James Brumley, InvestorPlace Feature Writer
None of the market's major pharmaceutical stocks are in the same boat. Here's the main thing investors need to know about each.

New Drug Could Cut ‘Bad’ Cholesterol Nearly in Half

By Christopher Freeburn, InvestorPlace Writer
Late stage trials of Alirocumab, an anti-cholesterol drug from Regeneron and Sanofi, showed promising results.

Flu Season Is Coming — And These Companies Are Ready

By Alyssa Oursler, InvestorPlace Contributor
Flu season is slowly getting started -- bad news for us, but welcome news for companies that benefit from flu sufferers' ills. Here's a look at some of them.

Biotech Blowout: 3 Stocks Taking a Hit

By Adam Benjamin, InvestorPlace Assistant Editor
The risky side of biotech stocks reared its ugly head in the past couple of days, sending three stocks to the mat in the wake of bad news.

Should I Buy GlaxoSmithKline (GSK)? 3 Pros, 3 Cons

By Dan Burrows, InvestorPlace Feature Writer
GlaxoSmithKline is seeking approval for the world's first malaria vaccine, but high debt and low growth mean investors should think twice before buying.
Load More